Genenta Science (GNTA) Competitors $4.04 +0.16 (+3.98%) As of 09:30 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock GNTA vs. ATAI, PVLA, AURA, CYRX, GLUE, PHAT, RNAC, TSVT, MNPR, and SEPNShould you be buying Genenta Science stock or one of its competitors? The main competitors of Genenta Science include Atai Life Sciences (ATAI), Palvella Therapeutics (PVLA), Aura Biosciences (AURA), Cryoport (CYRX), Monte Rosa Therapeutics (GLUE), Phathom Pharmaceuticals (PHAT), Cartesian Therapeutics (RNAC), 2seventy bio (TSVT), Monopar Therapeutics (MNPR), and Septerna (SEPN). These companies are all part of the "pharmaceutical products" industry. Genenta Science vs. Atai Life Sciences Palvella Therapeutics Aura Biosciences Cryoport Monte Rosa Therapeutics Phathom Pharmaceuticals Cartesian Therapeutics 2seventy bio Monopar Therapeutics Septerna Genenta Science (NASDAQ:GNTA) and Atai Life Sciences (NASDAQ:ATAI) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their valuation, media sentiment, analyst recommendations, institutional ownership, risk, dividends, earnings, profitability and community ranking. Which has preferable earnings & valuation, GNTA or ATAI? Genenta Science has higher earnings, but lower revenue than Atai Life Sciences. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGenenta ScienceN/AN/A-$12.60MN/AN/AAtai Life Sciences$308K976.27-$40.22M-$0.93-1.62 Which has more risk & volatility, GNTA or ATAI? Genenta Science has a beta of 0.66, meaning that its stock price is 34% less volatile than the S&P 500. Comparatively, Atai Life Sciences has a beta of 1.24, meaning that its stock price is 24% more volatile than the S&P 500. Is GNTA or ATAI more profitable? Genenta Science's return on equity of 0.00% beat Atai Life Sciences' return on equity.Company Net Margins Return on Equity Return on Assets Genenta ScienceN/A N/A N/A Atai Life Sciences N/A -65.75%-52.71% Do analysts rate GNTA or ATAI? Genenta Science currently has a consensus target price of $25.00, suggesting a potential upside of 518.05%. Atai Life Sciences has a consensus target price of $10.50, suggesting a potential upside of 597.67%. Given Atai Life Sciences' higher probable upside, analysts clearly believe Atai Life Sciences is more favorable than Genenta Science.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Genenta Science 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Atai Life Sciences 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the MarketBeat Community favor GNTA or ATAI? Atai Life Sciences received 327 more outperform votes than Genenta Science when rated by MarketBeat users. However, 87.50% of users gave Genenta Science an outperform vote while only 66.53% of users gave Atai Life Sciences an outperform vote. CompanyUnderperformOutperformGenenta ScienceOutperform Votes787.50% Underperform Votes112.50%Atai Life SciencesOutperform Votes33466.53% Underperform Votes16833.47% Does the media favor GNTA or ATAI? In the previous week, Genenta Science had 1 more articles in the media than Atai Life Sciences. MarketBeat recorded 2 mentions for Genenta Science and 1 mentions for Atai Life Sciences. Atai Life Sciences' average media sentiment score of 1.89 beat Genenta Science's score of 0.94 indicating that Atai Life Sciences is being referred to more favorably in the news media. Company Overall Sentiment Genenta Science Positive Atai Life Sciences Very Positive Do insiders and institutionals hold more shares of GNTA or ATAI? 15.1% of Genenta Science shares are owned by institutional investors. Comparatively, 28.4% of Atai Life Sciences shares are owned by institutional investors. 29.0% of Genenta Science shares are owned by company insiders. Comparatively, 31.2% of Atai Life Sciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. SummaryAtai Life Sciences beats Genenta Science on 8 of the 13 factors compared between the two stocks. Get Genenta Science News Delivered to You Automatically Sign up to receive the latest news and ratings for GNTA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GNTA vs. The Competition Export to ExcelMetricGenenta ScienceBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$73.98M$2.96B$5.51B$7.93BDividend YieldN/A1.89%5.11%4.22%P/E RatioN/A30.1522.5518.49Price / SalesN/A494.70394.97102.66Price / CashN/A168.6838.1834.62Price / Book3.343.166.694.25Net Income-$12.60M-$72.35M$3.22B$248.31M7 Day Performance3.19%0.47%1.11%1.12%1 Month Performance2.93%7.67%3.59%3.68%1 Year Performance22.95%-22.98%15.65%5.19% Genenta Science Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GNTAGenenta Science2.2568 of 5 stars$4.05+4.0%$25.00+518.0%+26.3%$73.98MN/A0.007Short Interest ↑News CoverageATAIAtai Life Sciences2.6873 of 5 stars$1.42-3.4%$10.50+639.4%-24.2%$283.69M$308,000.00-1.7580Positive NewsPVLAPalvella Therapeutics3.4225 of 5 stars$25.45+4.5%$44.43+74.6%N/A$280.43M$42.81M-2.10N/AAnalyst ForecastHigh Trading VolumeAURAAura Biosciences2.3377 of 5 stars$5.57+3.9%$22.75+308.4%-21.2%$279.75MN/A-3.2250Upcoming EarningsShort Interest ↑News CoveragePositive NewsCYRXCryoport2.3918 of 5 stars$5.52-0.5%$11.67+111.4%-65.5%$275.50M$228.39M-1.631,020Earnings ReportNews CoverageGap UpGLUEMonte Rosa Therapeutics1.9756 of 5 stars$4.46-2.0%$15.50+247.5%-7.7%$274.34M$75.62M-2.4490Upcoming EarningsShort Interest ↑News CoveragePHATPhathom Pharmaceuticals4.0484 of 5 stars$3.90-3.2%$21.83+459.8%-52.5%$271.58M$55.25M-0.69110Earnings ReportNews CoveragePositive NewsGap DownRNACCartesian Therapeutics1.9639 of 5 stars$10.34-1.5%$42.14+307.6%-45.6%$267.88M$38.91M-0.2064Upcoming EarningsGap DownTSVT2seventy bio1.7601 of 5 stars$4.99+0.2%$5.60+12.2%+9.4%$261.17M$37.86M-2.68440Short Interest ↑News CoverageMNPRMonopar Therapeutics2.8731 of 5 stars$42.71+7.9%$55.33+29.6%+1,167.1%$261.09MN/A-21.6810Upcoming EarningsNews CoverageGap DownSEPNSepterna2.2586 of 5 stars$5.87-0.5%$33.00+462.2%N/A$260.88M$1.08M0.00N/ANews CoveragePositive News Related Companies and Tools Related Companies Atai Life Sciences Competitors Palvella Therapeutics Competitors Aura Biosciences Competitors Cryoport Competitors Monte Rosa Therapeutics Competitors Phathom Pharmaceuticals Competitors Cartesian Therapeutics Competitors 2seventy bio Competitors Monopar Therapeutics Competitors Septerna Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:GNTA) was last updated on 5/1/2025 by MarketBeat.com Staff From Our PartnersHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredIs he more powerful than Trump? Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredTrump and Buffett Are Quietly Leading America’s Gold RevivalThe “Buffett Indicator” Predicts Gold Set To Dominate for Next Decade Each time the Buffett Indicator has...Golden Portfolio | SponsoredThis isn’t a trade war. It’s worse…Investigative Journalist Bombhsell: The Curse on the U.S Dollar Depleted retirement accounts? Meme coin inv...Stansberry Research | SponsoredElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredElon Musk’s next move from the Oval Office?No one is closer to President Trump than Tesla CEO Elon Musk. He's been dubbed Trump's "first buddy." Tr...Weiss Ratings | SponsoredTrump Treasure April 19Thanks to President Trump… A $900 investment across5 specific cryptos… Could gain 12,000% so quickly tha...Paradigm Press | SponsoredThey rigged the gameThe U.S. fired the first shot with 145% tariffs. Apple relies heavily on Chinese production. Tesla needs Ch...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Genenta Science S.p.A. Please log in to your account or sign up in order to add this asset to your watchlist. Share Genenta Science With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy GNTA Stock Free GNTA Stock Alerts